Oculis to Participate in Upcoming November Investor Conferences

Core Insights - Oculis Holding AG is advancing its late-stage portfolio in neuro-ophthalmology and ophthalmology, entering a pivotal phase to become a leader in these fields [2][8] - The company is preparing for registrational trials for its key product candidates, including Privosegtor for acute optic neuritis and NAION, with positive feedback from the FDA [2][8] - Oculis has a strong balance sheet and is positioned to deliver six pivotal readouts with current funding, aiming to improve eye care with innovative treatments [3] Upcoming Events - Oculis management will participate in several investor conferences in November, including the Guggenheim Securities Healthcare Innovation Conference and the Stifel Healthcare Conference [4][5] - Riad Sherif, M.D., CEO of Oculis, will engage in fireside chats and panel discussions at these conferences, providing insights into the company's strategies and developments [4][5][7] - The company will also hold one-on-one meetings with investors during these events, facilitating direct engagement [6][7] Product Pipeline - Oculis' late-stage clinical pipeline includes three core product candidates: - Privosegtor, targeting optic neuropathies with broad clinical applications [8] - OCS-01, aiming to be the first non-invasive topical treatment for diabetic macular edema, with topline results expected in Q2 2026 [2][8] - Licaminlimab, a novel anti-TNFα treatment for dry eye disease, developed with a genotype-based approach [2][8]